PCRX
Pacira BioSciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PCRX
Pacira Biosciences, Inc.
The industry leader in its commitment to non-opioid pain management and regenerative health solutions
2000 Sierra Point Parkway, Ninth Floor, Brisbane, California 94005
--
Founded in December 2006, Pacira BioSciences, Inc., has been conducting business related to EXPAREL since March 2007. The company is a specialty pharmaceutical company specializing in the development, commercialization and manufacture of pharmaceutical products based on the company's proprietary DepoFoam drug delivery technology, mainly used in hospitals and outpatient surgical centers. The company operates a reportable division. On October 28, 2011, the U.S. Food and Drug Administration (FDA) approved the Company's New Drug Application, or NDA, for the Company's lead product candidate, EXPAREL, a liposomal injection of bupivacaine, an amide-type local anesthetic suitable for infiltration into the surgical site to produce postoperative analgesia for up to 72 hours. The Company believes that EXPAREL addresses a significant unmet medical need for long-acting non-opioid postoperative analgesics, simplifying postoperative pain management and reducing opioid consumption, resulting in improved patient outcomes and improved hospital economics. The Company has developed an in-house sales force fully committed to commercializing EXPAREL, which the Company commercialized in April 2012. In addition, following the pilot program, effective October 1, 2013, the Company appointed CrossLink BioScience, LLC or CrossLink as the exclusive third-party distributor for a period of five years to promote and sell EXPAREL for orthopedic and spinal surgery in the United States, with the exception of certain geographic regions and accounts, which may be changed and adjusted according to the mutual agreement.
Earnings Call
Q1/2025
Estimate EPS0.6
Actual EPS0.62
Estimate Revenue175.88M
Actual Revenue168.92M
Pacira BioSciences Q1 2025: Key Contradictions in EXPAREL's Market Strategy and Patent Protection
May 19,2025 09:56
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.71
Actual EPS0.74
Estimate Revenue182.76M
Actual Revenue180.35M
Pacira BioSciences' Q2 2025: Contradictions Surface on EXPAREL Market Access, Sales, and Margins
Aug 06,2025 02:49
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PCRX has released its 2025 Q3 earnings. EPS was reported at 0.7, versus the expected 0.65, beating expectations. The chart below visualizes how PCRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PCRX has released its 2025 Q3 earnings report, with revenue of 179.52M, reflecting a YoY change of 6.49%, and net profit of 5.43M, showing a YoY change of 103.79%. The Sankey diagram below clearly presents PCRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
